Drug
Sulfadoxine-Pyrimethamine (Fansidar)
Sulfadoxine-Pyrimethamine (Fansidar) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_4
2
50%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)
Trials by Status
completed250%
unknown250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children
NCT00137553
unknownnot_applicable
IPTp Plus ITNs for Malaria Control in Pregnant Women
NCT00209781
unknownphase_1
IPTi in Mozambican Infants for Malaria Prevention
NCT00209794
completedphase_4
Intermittent Preventive Treatment of Malaria in HIV-Seropositive Pregnant Women in Zambia
NCT00270530
Clinical Trials (4)
Showing 4 of 4 trials
NCT00137553Phase 4
The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children
NCT00209781Not Applicable
IPTp Plus ITNs for Malaria Control in Pregnant Women
NCT00209794Phase 1
IPTi in Mozambican Infants for Malaria Prevention
NCT00270530Phase 4
Intermittent Preventive Treatment of Malaria in HIV-Seropositive Pregnant Women in Zambia
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4